BioScrip, Inc. (NASDAQ:BIOS) CFO Stephen Deitsch purchased 10,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $20,300.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at $20,300. The purchase was disclosed in a filing with the SEC, which is available through this link.
BioScrip, Inc. (BIOS) traded up $0.03 during trading on Monday, hitting $2.11. 781,900 shares of the stock traded hands, compared to its average volume of 1,754,143. BioScrip, Inc. has a one year low of $0.98 and a one year high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The firm had revenue of $198.70 million for the quarter, compared to the consensus estimate of $202.91 million. BioScrip’s revenue was down 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.12) EPS. research analysts expect that BioScrip, Inc. will post -0.63 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/13/insider-buying-bioscrip-inc-bios-cfo-buys-10000-shares-of-stock.html.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its stake in BioScrip by 65.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock valued at $109,000 after buying an additional 25,500 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in BioScrip in the 3rd quarter valued at about $114,000. American International Group Inc. grew its stake in BioScrip by 73.8% in the 1st quarter. American International Group Inc. now owns 67,812 shares of the company’s stock valued at $115,000 after buying an additional 28,787 shares during the last quarter. Captrust Financial Advisors acquired a new position in BioScrip in the 2nd quarter valued at about $123,000. Finally, Voya Investment Management LLC grew its stake in BioScrip by 41.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after buying an additional 14,867 shares during the last quarter. Institutional investors and hedge funds own 83.00% of the company’s stock.
Several equities research analysts have commented on BIOS shares. BidaskClub cut shares of BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. SunTrust Banks, Inc. restated a “buy” rating and set a $3.00 price objective on shares of BioScrip in a research note on Friday, November 3rd. Jefferies Group LLC restated a “buy” rating and set a $4.00 price objective (up from $3.00) on shares of BioScrip in a research note on Thursday, August 10th. ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research lowered shares of BioScrip from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $3.60.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.